Stingthera, Inc. Announces Clinical Collaboration with Merck to Evaluate SNX281 in Combination With KEYTRUDA® (pembrolizumab) in Certain Patients with Advanced Solid Tumors and Lymphoma
November 03, 2021 06:45 ET
|
Stingthera, Inc.
BOSTON, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Stingthera, Inc. today announced it has entered into a clinical trial collaboration agreement with Merck (known as MSD outside the United States and Canada)...